METiS and Eli Lilly Partner on Tissue-Specific LNP Delivery in Deal Worth Up to About 1.1 Billion Dollars

On October 19, METiS Pharmaceuticals and Eli Lilly announced a strategic collaboration on tissue-specific LNP delivery, aiming to develop tissue-targeting technologies for multiple therapeutic modalities. METiS will receive an upfront payment of over ten million US dollars and is eligible for development, regulatory and commercial milestone payments totaling up to approximately 1.1 billion US dollars, plus tiered royalties at a single-digit percentage of annual net sales of collaboration products. The article also describes YXgene's Ab-LNP platform, reporting that hCD8 antibody-conjugated tLNP achieved an 87.7% positive rate against CD8+ T cells, and that sample preparation spans microgram-to-milligram-to-gram scales.